Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.
Canada’s Federal Court ruled recently that the country’s Patented Medicine Prices Review Board — a federal tribunal that regulates pricing on branded medicines — could not extend price-control measures to cover generic drug companies, according to published reports.
A survey co-released on Wednesday by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that the healthcare providers patients rely on most to explain safety information about their prescription drugs have serious concerns about a proposed FDA rule on generic drug labeling.
A survey co-released Wednesday by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that 8-in-10 healthcare providers have serious concerns about a proposed Food and Drug Administration rule on generic drug labeling.
New approaches to treating cancer are creating big growth opportunities for the pharmaceutical industry, Moody's Investors Service stated in a report released Thursday titled "Cancer Breakthroughs Bring New Options for Patients and Revenue Streams to Big Pharma."
Teva Pharmaceutical Industries on Thursday announced that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb's entecavir compound claim of U.S. Patent No. 5,206,244 invalid.
Valeant Pharmaceuticals International announced that its subsidiary, Valeant Pharmaceuticals North America, received approval from the Food and Drug Administration for its new drug application for Jublia (efinaconazole 10% topical solution). The drug is the first topical triazole approved for the treatment of onychomycosis of the toenails, the company said.
The House Energy and Commerce Committee on Tuesday advanced bipartisan legislation sponsored by full committee vice chair Marsha Blackburn to address the nation’s growing prescription drug abuse epidemic.
Canada’s Federal court ruled recently that the country’s Patented Medicine Prices Review Board – a federal tribunal that regulates pricing on branded medicines – could not extend price control measures to cover generic drug companies.
A recently approved drug might make infusions for hemophiliacs fewer and further between. The Food and Drug Administration approved Biogen Idec's Eloctate, which clinical trials have shown works to treat bleeding episodes and to increase the time between prophylactic blood infusions for those with hemophilia A.
Teva Pharmaceutical Industries on Monday announced a new organizational structure and executive positions. The changes, which will become effective July 1, are designed to improve global integration and effectiveness across the company, Teva said.
Prasco Labs on Thursday announced it has entered into a distribution and supply agreement with Recordati Rare Diseases for the rights to distribute ibuprofen lysine injection, the authorized generic version of NeoProfen (ibuprofen lysine).
Abbott announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence the company reported.
The Generic Pharmaceutical Association lobbied for greater access to generics at this week’s meeting of the chief negotiators of the Trans-Pacific Partnership in Ho Chi Minh City, Vietnam, the association announced Wednesday.